Pharma’s dirty deals to stall generics
As generic companies, including Indian firms, collude with innovator pharma giants in pay-for-delay pacts, consumers pay a high price
Fading history of Novartis v Union of India
The 2013 landmark Supreme Court judgement offers critical lessons on the intent behind crucial aspects of India’s key patent law
High Court notice to Novartis on Cipla appeal
Cipla has challenged the court order restraining it from manufacturing generic version of respiratory ailment drug
Italy suspends Novartis vaccine after four patients die
Tests are on to find if there is a causal link; Swiss pharmaceutical boasts of the drug’s safety record
A victory and a retreat on CLs
Supreme Court upholds India's first compulsory licence but government baulks at giving the second
Why scientists don’t back Novartis claim
As Novartis’ Indian patent case reaches end, a reminder of how scientists view unfair patents
India’s 3 D Message
The Supreme Court judgment in the Novartis case clearly upholds India’s patent laws, not weakens the patent regime
Cipla's audacious move
Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug
Gopal Subramaniam, Rohinton Nariman swap places in Novartis patent case
Will take on each other in the patent case of anti-cancer drug Glivec filed by Novartis
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …
Big pharma’s dirty tricks
Drug giants from GSK, Abbott and Pfizer to Bayer have been fined for serious malpractices. They should be under close watch in India
Novartis loses patent appeal in landmark suit
Supreme Court upholds amended law that bars patents for insignificant improvements to an existing drug—in this case anti-cancer drug …
Malaria drug-resistant parasite common in Southeast Asia: study
The problem could get much worse if the parasite reaches Africa, warn experts
Sun Pharma, Novartis settle lawsuit over Glivec
Sun Pharma allowed to launch generic version of anti-leukamia drug next year